SecBot SecBot
S-1/A ·Filed Jun 16, 2026

BIAF

bioAffinity Technologies, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed4mo ago SEC0001493152-26-028877
IPO registration amendment
Actionable Insight • Neutral

Monitor for pricing and closing of the offering; the company's cash runway is critical given the going-concern warning. The procedural filing does not change the bearish fundamental outlook from the prior S-1.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
BIAF ▼ -36.44% at T+60d
NEUTRAL call -36.44% · α vs SPY -39.13% · entry $0.8318 → $0.5287
Entry = T+0 close
Jun 16, 2026
via day close
T+1d
+0.65%
call +0.65% · α -0.13%
$0.8372
settled 4mo ago
T+5d
+1.02%
call +1.02% · α +1.92%
$0.8403
settled 4mo ago
T+20d
-15.40%
call -15.40% · α -15.71%
$0.7037
settled 3mo ago
T+60d
-36.44%
call -36.44% · α -39.13%
$0.5287
settled 7w ago

Executive Summary

bioAffinity Technologies filed Amendment No. 1 to its S-1 registration statement, a procedural update adding the Placement Agency Agreement and forms of Pre-Funded and Placement Agent Warrants. The offering terms remain undisclosed, and the company's going-concern warning and declining revenue persist from the prior filing. This amendment does not alter the material terms or financial outlook.

Key Facts

  • Amendment No. 1 to S-1 filed June 16, 2026, adding Exhibit 1.1 (Placement Agency Agreement) and Exhibits 4.44/4.45 (warrant forms).
  • Placement agent WallachBeth Capital receives 7.5% cash fee, up to $120,000 expense reimbursement, and warrants equal to 3% of shares sold.
  • Offering size and pricing remain undisclosed (placeholders $[*] in the agreement).
  • Company has a going-concern warning, $3.1M cash (as of March 31, 2026 per prior filing), and accumulated deficit of $72.2M.

Financial Impact

Undisclosed offering size; prior S-1 targeted ~$3.4M net proceeds. This amendment does not change the financial terms.

dilutioncash position

Risk Factors

  • Going-concern risk with limited cash and accumulated losses.
  • Significant dilution from the offering and outstanding warrants/preferred stock.
  • Revenue decline of 36% YoY in Q1 2026 (per prior filing).

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-1/A Filing (Primary)0001493152-26-028877
Exhibit: ex4-45.htm0001493152-26-028877
Exhibit: ex1-1.htm0001493152-26-028877
28 reports for BIAF
Performance horizon
62% Hit rate @ T+1 8 of 13 directional calls Went positive at some point 9 of 13 best @ T+20▲ +59.46%Sep 3, 2026
Filters
Rows
Reports for BIAF — sortable, filterable
TypeNow
Oct 23, 2026
3d ago
DEF 14A
NEUTRAL ★ 5/10
$2.81awaiting T+1—$2.83 (+0.71%)
Oct 15, 2026
11d ago
8-K
NEUTRAL ★ 3/10
$3.96 $3.73▼ −5.81%▼ −4.70%$2.83 (−28.54%)
Oct 13, 2026
13d ago
8-K
NEUTRAL ★ 3/10
$3.63 $3.56▼ −1.79%▼ −0.71%$2.83 (−21.93%)
Oct 9, 2026
17d ago
8-K
BEARISH ★ 6/10
$3.90 $3.63▲ +7.05%▲ +7.04%$2.83 (+27.44%)
Oct 9, 2026
17d ago
424B5
BEARISH ★ 7/10
$4.73 $3.90▲ +17.46%▲ +17.40%$2.83 (+40.11%)
Oct 9, 2026
17d ago
424B5
NEUTRAL ★ 4/10
$4.73 $3.90▼ −17.46%▼ −17.40%$2.83 (−40.11%)
Oct 8, 2026
18d ago
8-K
BULLISH ★ 4/10
$5.64 $4.73▼ −16.22%▼ −16.82%$2.83 (−49.82%)
Oct 6, 2026
20d ago
8-K
BULLISH ★ 5/10
$6.06 $6.16▲ +1.65%▲ +1.89%$2.83 (−53.30%)
Sep 30, 2026
26d ago
8-K
NEUTRAL ★ 3/10
$6.56 $6.15▼ −6.33%▼ −6.50%$2.83 (−56.86%)
Sep 22, 2026
4w ago
8-K
NEUTRAL ★ 2/10
$8.56 $7.94▼ −7.19%▼ −6.47%$2.83 (−66.92%)
Showing 10 of 28

US Market Status

Market Closed — Opens in 2h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026